质量改进项目改善血液透析华法林治疗达标时间
该研究针对血液透析华法林治疗患者,通过审计反馈报告的质量改进项目,将TTR>60%的患者比例从基线40%提高至干预后61%,并显示持续改善。
要点
- 审计反馈报告可提高透析患者华法林TTR达标率。
- 基线TTR>60%达标率仅40%,干预后升至61%。
- 质量改进项目可持续改善抗凝安全管理。
核心结论
- 包含审计反馈报告的质量改进项目可显著提高维持性血液透析患者华法林治疗TTR达标率。
研究设计与样本
- 单中心质量改进研究,基线期28例,干预期46例,采用计划-执行-研究-行动循环和统计过程控制分析。
主要发现
- 基线期TTR>60%的患者比例在33%至45%之间(均值±标准差40%±5%)。
- 干预期TTR>60%的患者比例在52%至71%之间(均值±标准差61%±8%)。
- 时间序列分析显示两期之间差异有统计学意义且改善持续。
关键数值与推荐
- TTR>60%为华法林治疗目标,与较低出血风险相关。
临床怎么用
- 可向华法林处方医生定期反馈患者个体化TTR趋势报告以缩小质量差距。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Studies have shown that achieving a time in therapeutic range (TTR) for warfarin of greater than 60% is associated with a lower risk of bleeding. However, many patients on hemodialysis (HD) do not achieve this target. METHODS: We audited TTR achievement at the in-center HD unit of our hospital in 2017 and found that only 40% of patients had achieved a TTR >60%. We aimed to improve the percentage of HD patients achieving target TTR within 2 years. We reported each patient's individualized trend in quarterly TTR to their primary warfarin prescriber as an audit-feedback report. These reports were generated, disseminated, and subsequently improved following a series of plan-do-study-act cycles. We then used statistical process control to assess for changes in the percentage of HD patients achieving target TTR over time. RESULTS: In the primary analysis, 28 patients were included in the baseline period, and 46 were included in the intervention period. At baseline, the percentage of patients achieving a TTR >60% varied between 33% and 45% (mean ± SD, 40% ± 5%); post-intervention, this metric improved and varied between 52% and 71% (mean ± SD, 61% ± 8%). In time-series analysis, there was evidence of statistically significant variation between the 2 periods and evidence of sustained improvement. CONCLUSIONS: A quality improvement program consisting of an audit-feedback report that raises awareness of the quality gap in TTR achievement can result in substantial improvement in the safe and efficacious administration of warfarin to patients receiving maintenance hemodialysis.
引用
- Blum D, Beaubien-Souligny W, Battistella M, et al. Quality Improvement Program Improves Time in Therapeutic Range for Hemodialysis Recipients Taking Warfarin. Kidney Int Rep. 2019. PMID: 32043029. doi:10.1016/j.ekir.2019.10.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。